Clinical trials: Precocious Puberty, Central
Central Precocious Puberty
Histrelin Subcutaneous Implant in Children With Central Precocious Puberty
The purpose of this study is to follow and collect additional medical and developmental information on children after histrelin subcutaneous implant therapy is discontinued.
- Trial name
- NCT00779103
- Testing
- Histrelin Subcutaneous Implant
- Volunteers
- 36 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Central Precocious Puberty
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial)
The primary objective of this study is to evaluate the efficacy of Debio 4326 in suppressing serum luteinizing hormone (LH) to prepubertal levels 52 weeks after the first Debio 4326 injection in pediatric participants with…
- Trial name
- NCT06129539
- Testing
- Debio 4326
- Where
- 17 sites in United States, Argentina and 3 more
- Volunteers
- 56 people
- Sponsor
- Debiopharm International SA
Central Precocious Puberty
The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty
The purpose of this Clinical Trial was to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide acetate 3.75mg) in patients with precocious puberty.
- Trial name
- NCT01634321
- Testing
- Luphere depot 3.75mg(Leuprolide acetate 3.75mg)
- Where
- South Korea
- Volunteers
- 63 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Central Precocious Puberty
A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants
The purpose of this study is to assess long-term safety and efficacy of leuprorelin in the treatment of Central Precocious Puberty (CPP).
- Trial name
- NCT02427958
- Testing
- Leuprorelin
- Where
- 9 sites in China
- Volunteers
- 307 people
- Sponsor
- Takeda
Precocious, Leuprolide Acetate
Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty
The purpose of this extension study is to determine if leuprolide acetate (11.25 mg and 30 mg) is safe in treating children with Central Precocious Puberty over a longer period of time (36 months).
- Conditions
- Precocious, Leuprolide Acetate, Luteinizing Hormone (LH), Gonadotrophin-releasing Hormone Agonist (GnRHa)
- Trial name
- NCT00667446
- Testing
- Leuprolide Acetate 3 Month Depot
- Where
- 20 sites in United States, Puerto Rico
- Volunteers
- 72 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Puberty; Precocious, Central
Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty
The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with central (gonadotropin-dependent) precocious puberty, when administered as two injections six months apart.
- Trial name
- NCT05493709
- Testing
- Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide
- Where
- 41 sites in United States, China and 2 more
- Volunteers
- 94 people
- Sponsor
- Foresee Pharmaceuticals Co., Ltd.
Central Precocious Puberty
Evaluate the Efficacy and Safety of DWJ108J
This study aims to evaluate the efficacy and safety of DWJ108J (Leuprorelin acetate 11.25 mg) in patients with central precocious puberty.
- Trial name
- NCT06025409
- Testing
- Leuprolide Acetate 11.25 MG/ML
- Where
- South Korea
- Volunteers
- 79 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Central Precocious Puberty (CPP)
A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)
The primary objective of the study is to assess the safety and efficacy of a leuprolide acetate (LA) 45 mg 6-month depot formulation for the treatment of CPP in children who are either naïve to treatment with a…
- Trial name
- NCT03695237
- Testing
- Leuprolide Acetate (LA)
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 45 people
- Sponsor
- AbbVie
Central Precocious Puberty
Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty
The study will investigate the efficacy, safety and pharmacokinetics of triptorelin 22.5 mg 6-month formulation in 44 patients suffering from central precocious puberty.
- Trial name
- NCT01467882
- Testing
- Triptorelin
- Where
- 13 sites in United States, Chile and 1 more
- Volunteers
- 44 people
- Sponsor
- Debiopharm International SA
CPP
Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious Puberty
This study is a multicenter, open-label, single-group, and phase 4 study to evaluate the efficacy and safety of 45 mg of leuprolide acetate in CPP.
- Trial name
- NEST (NCT06926933)
- Testing
- Eligard® 45 mg
- Where
- 9 sites in South Korea
- Volunteers
- 50 people
- Sponsor
- HanAll BioPharma Co., Ltd.
Central Precocious Puberty
A Study of Medical Records From Children With Central Precocious Puberty (CPP) in China
The main purpose is to describe how many children were treated during 24 months or less because of CPP and how treatment worked for them.
- Trial name
- PACTURE (NCT05341128)
- Where
- 5 sites in China
- Volunteers
- 1,477 people
- Sponsor
- Takeda
Puberty, Precocious
Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis]
The primary objective of this study is to investigate whether bicalutamide given in combination with anastrozole once daily for 12 months is effective in treating testotoxicosis in boys.
- Trial name
- BATT (NCT00094328)
- Testing
- Bicalutamide, Anastrozole
- Where
- 15 sites in United States, Canada and 4 more
- Volunteers
- 14 people
- Sponsor
- AstraZeneca
Precocious Puberty, Central
Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty
This study determines the effectiveness of leuprolide acetate 45 mg for injectable suspension for treatment of children with Central Precocious Puberty.
- Trial name
- NCT02452931
- Testing
- Leuprolide Acetate 45 mg
- Where
- 20 sites in United States, Argentina and 4 more
- Volunteers
- 64 people
- Sponsor
- Tolmar Inc.
Puberty, Precocious
A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty
The purpose of this study is to determine if 11.25 and 30 mg formulations of leuprolide are effective in treating children with Central Precocious Puberty (CPP).
- Trial name
- NCT00635817
- Testing
- Leuprolide acetate 11.25 mg, Leuprolide acetate 30 mg
- Where
- 25 sites in United States, Puerto Rico
- Volunteers
- 84 people
- Sponsor
- Abbott
Central Precocious Puberty
Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty.
The purpose of this research was to confirm the effectiveness and safety of the study drug, Triptorelin pamoate 15mg 3-month formulation, in a Chinese population of Central Precocious Puberty (CPP) children.
- Trial name
- NCT04736602
- Testing
- Triptorelin pamoate 15mg
- Where
- 7 sites in China
- Volunteers
- 32 people
- Sponsor
- Ipsen
Central Precocious Puberty
A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants
The purpose of this study is to evaluate the long-term safety and efficacy of Enantone in the treatment of CPP in Chinese participants.
- Trial name
- NCT02993926
- Testing
- Enantone, GnRH agonist
- Where
- 6 sites in China
- Volunteers
- 108 people
- Sponsor
- Takeda
Central Precocious Puberty
A Study of Leuprorelin 1-Month (4-Week) Formulation in Children With Central Precocious Puberty
A Single-Arm, Open-Label, Multicenter, Prospective Clinical Study to Evaluate the Effectiveness and Safety of Leuprorelin 1-Month (4-Week) Formulation Administered for 24 Months in Children with Central Precocious Puberty
- Trial name
- NCT07710430
- Testing
- Leuprorelin
- Where
- South Korea
- Volunteers
- 43 people
- Sponsor
- LG Chem
Central Precocious Puberty
A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.
The purpose of the protocol is to assess the efficacy of the triptorelin 6 month PR (Prolonged Release) formulation in suppressing LH (Luteinising hormone) levels to prepubertal levels (defined as a peak LH ≤5 IU/L) after i.v.
- Trial name
- NCT05029622
- Testing
- Triptorelin Pamoate
- Where
- 14 sites in China
- Volunteers
- 66 people
- Sponsor
- Ipsen
Central Precocious Puberty
A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty
The main aim is to see how leuprolide works to treat central precocious puberty in children. Participants will receive an injection of leuprorelin acetate depot 11.25 mg every 12 weeks during 6 months and will visit their study…
- Trial name
- PUPIL (NCT05341115)
- Testing
- Leuprorelin Acetate Depot 3M
- Where
- 5 sites in China
- Volunteers
- 79 people
- Sponsor
- Takeda
Puberty, Precocious
Study of Lupron Depot In The Treatment of Central Precocious Puberty
The purpose of this study is to determine if Lupron (leuprolide acetate) is safe and effective in treating children with Central Precocious Puberty (CPP), and to assess long term effects of leuprolide acetate treatment after…
- Trial name
- NCT00660010
- Testing
- Lupron (leuprolide acetate)
- Where
- 9 sites in United States
- Volunteers
- 55 people
- Sponsor
- Abbott